Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Commissioners Seem POM-Skeptical In Claims Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

“The idea that this company has built these health claims on bogus science is wrong,” says POM Wonderful counsel Edward Lazarus. But commissioners reviewing appeals of FTC’s challenge against POM’s claims for its pomegranate products appeared to believe the company made a number of implied disease claims.

You may also be interested in...



POM Wonderful Says Interviews Fall Outside FTC Advertising Scope

Claims about the benefits of pomegranate made in unpaid-for media appearances should not qualify as “advertising” under the FTC Act, argues POM Wonderful. Among the claims FTC is pursuing, POM owner Lynda Resnick told Newsweek that pomegranate juice is “40 percent as effective as Viagra.”

Judge Knocks Down FTC Substantiation Bar In POM Wonderful Case

An FTC administrative law judge says the agency cannot require randomized controlled trials to substantiate nutrient claims. POM Wonderful calls the decision “a huge win,” but the firm still received a cease-and-desist order for its pomegranate juice and supplement claims.

Market America Asked To Comb Records For Serious AERs About Its Supplements

An FDA inspection found two serious adverse event reports Market America received were not forwarded to the agency as required. Its response didn't answer whether it would review its records "to determine if a serious adverse event report should be submitted to FDA.”

Topics

Related Companies

UsernamePublicRestriction

Register

PS074724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel